LAUSANNE, Switzerland, July 11, 2011 /PRNewswire/ --
EffRx Pharmaceuticals SA, an Epalinges/Lausanne, Switzerland
based drug delivery company, announces that US patent 7,964,212 was
issued on June 21, 2011, enhancing the protection of EX101.
This patent grants significant additional Intellectual Property
concerning the EffRx Lead Program, EX101 (70 mg effervescent
alendronate for the treatment of osteoporosis).
The extended range of intellectual property in this patent
protects effervescent formulations of all the orally administered
bisphosphonate osteoporosis medications including risedronate and
ibandronate, when delivered in the highly buffered EX101
formulation. The formulation is unique in that it delivers the
bisphosphonate to the stomach in a proprietary buffered solution
which prevents exposure of the stomach or esophagus to strongly
acidified bisphosphonate forms, which are believed to be damaging
forms of this drug class.
Additional claims related to the buffering composition and
method of manufacturing were also granted.
An NDA for EX101 has been filed by the FDA. Nycomed has licensed
EX101 for territories outside the United States, Canada and Japan,
and the product is in registration in many countries.
"There are more and more reports around the world that generic
alendronate products have even more GI-side effect problems and
thereby less patient compliance than branded bisphosphonate
products. We strongly believe that EX101 fills an unmet need of
patients, doctors, and payers around the world since poor
compliance leads to escalating health costs due to osteoporosis
related fractures" stated Christer Rosén, Chairman and CEO.
EffRx is a privately held drug delivery technology company
specializing in the utilization of proprietary effervescent
technology to develop formulations that improve efficiency,
compliance and convenience of existing prescription drugs.
For additional information please visit the EffRx website http://www.effrx.com
Chairman and CEO
SOURCE EffRx Pharmaceuticals S.A.